Article
Envision Pharma Group
The Amazing History and Evolution of Medical Affairs in 32 Minutes
Summary
In this episode, Tom Caravela is joined by Ralph Rewers to explore the history and evolution of Medical Affairs. They discuss the origins and progression of Medical Affairs, including the significance of the first MSL deployment. The conversation highlights the relevance of a medical background for MSLs and factors contributing to their deployment amidst modern scientific complexities. Key milestones and the future impact of AI and technology on Medical Affairs are examined, along with the importance of internal stakeholder relationships and the rise of patient centricity. The episode also delves into KOL interaction dynamics and the future of Medical Affairs, concluding with Ralph's reflections on his career and retirement.
Key Points
- Medical affairs serves as a crucial bridge between R&D and commercial teams, ensuring the scientific integrity and effective lifecycle management of pharmaceutical products. The role of MSLs has evolved significantly from simply supporting sales reps to becoming essential partners in conveying complex scientific information and fostering deep, trust-based relationships with healthcare providers. The future of medical affairs will likely incorporate advanced technologies like AI to augment human expertise, but the need for personal interaction and patient-centric focus will remain irreplaceable.
Medical Affairs, MSL deployment, AI in pharmaceuticals, patient centricity, KOL interaction
Related Topics
You May Also Like
Envision Pharma Group
Article
Envision Pharma Group
Medical affairs: The power behind redefining commercialization
Podcast
MSL Talk: Tom Caravela, Carsten Schnatwinkel, Jeanna Cooper
The Struggle With KOL Access in Todays World
Podcast
MSL Talk: Tom Caravela, Daniel Snyder
Interim Impact The Rise of Fractional Medical Affairs Roles in Pharmas New Reality
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois